{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T07:55:57Z","timestamp":1781337357426,"version":"3.54.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007859","name":"University of Kansas","doi-asserted-by":"publisher","award":["UL1TR002366"],"award-info":[{"award-number":["UL1TR002366"]}],"id":[{"id":"10.13039\/100007859","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA168524"],"award-info":[{"award-number":["P30 CA168524"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jcyt.2025.102012","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T07:57:00Z","timestamp":1764143820000},"page":"102012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A phase 1b study on the safety of Wharton\u2019s jelly mesenchymal stromal cells in the treatment of acute graft-versus-host disease"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9534-0512","authenticated-orcid":false,"given":"William","family":"Wesson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6472-9325","authenticated-orcid":false,"given":"Milind","family":"Phadnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyce","family":"Bruns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Balusu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitham","family":"Abdelhakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupal","family":"Soder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Abhyankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-4796","authenticated-orcid":false,"given":"Joseph P.","family":"McGuirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2025.102012_bib0001","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1182\/blood-2019-125232","article-title":"One and Half Million Hematopoietic Stem Cell Transplants (HSCT). Dissemination, Trends and Potential to Improve Activity By Telemedicine from the Worldwide Network for Blood and Marrow Transplantation (WBMT)","volume":"134","author":"Niederwieser","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.102012_bib0002","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41409-019-0624-z","article-title":"Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors","volume":"55","author":"Styczy\u0144ski","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.102012_bib0003","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.iac.2009.10.001","article-title":"Pathogenesis and management of graft-versus-host disease","volume":"30","author":"Choi","year":"2010","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jcyt.2025.102012_bib0004","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-023-00438-1","article-title":"Acute graft-versus-host disease","volume":"9","author":"Malard","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jcyt.2025.102012_bib0005","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.102012_bib0006","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood.2020004823","article-title":"Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial","volume":"135","author":"Jagasia","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.102012_bib0007","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.bbmt.2015.01.001","article-title":"A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality","volume":"21","author":"MacMillan","year":"2015","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1016\/j.jcyt.2025.102012_bib0008","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3324\/haematol.2019.220970","article-title":"Validation of Minnesota acute graft-versus-host disease Risk Score","volume":"105","author":"MacMillan","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2025.102012_bib0009","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41392-024-01987-x","article-title":"Ruxolitinib plus steroids for acute graft versus host disease: a multicenter, randomized, phase 3 trial","volume":"9","author":"Dou","year":"2024","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.jcyt.2025.102012_bib0010","unstructured":"Food and Drug Administration. FDA approves remestemcel-L-rknd for steroid-refractory acute graft versus host disease in pediatric patients.https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-remestemcel-l-rknd-steroid-refractory-acute-graft-versus-host-disease-pediatric; 2024. Accessed February 15, 2025."},{"key":"10.1016\/j.jcyt.2025.102012_bib0011","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3389\/fimmu.2019.01191","article-title":"Immunomodulation by Mesenchymal Stem Cells (MSCs): Mechanisms of Action of Living, Apoptotic, and Dead MSCs","volume":"10","author":"Weiss","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.102012_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.570179","article-title":"Biological Characteristics of Umbilical Cord Mesenchymal Stem Cells and Its Therapeutic Potential for Hematological Disorders","volume":"9","author":"Shang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jcyt.2025.102012_bib0013","doi-asserted-by":"crossref","first-page":"11692","DOI":"10.3390\/ijms140611692","article-title":"Wharton\u2019s jelly-derived mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications","volume":"14","author":"Kim","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcyt.2025.102012_bib0014","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"Von Elm","year":"2007","journal-title":"The Lancet"},{"key":"10.1016\/j.jcyt.2025.102012_bib0015","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s12015-020-10015-8","article-title":"A Phase I Study to Evaluate Two Doses of Wharton\u2019s Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host Disease","volume":"16","author":"Soder","year":"2020","journal-title":"Stem Cell Rev and Rep"},{"key":"10.1016\/j.jcyt.2025.102012_bib0016","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.jcyt.2024.07.003","article-title":"Microcarrier-based clinical-grade manufacturing of therapeutic Wharton\u2019s jelly mesenchymal stromal cells","volume":"26","author":"Soder","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.102012_bib0017","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.bbmt.2008.03.012","article-title":"Adult Human Mesenchymal Stem Cells Added to Corticosteroid Therapy for the Treatment of Acute Graft-versus-Host Disease","volume":"15","author":"Kebriaei","year":"2009","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1016\/j.jcyt.2025.102012_bib0018","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.bbmt.2013.11.001","article-title":"Allogeneic Human Mesenchymal Stem Cell Therapy (Remestemcel-L, Prochymal) as a Rescue Agent for Severe Refractory Acute Graft-versus-Host Disease in Pediatric Patients","volume":"20","author":"Kurtzberg","year":"2014","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1016\/j.jcyt.2025.102012_bib0019","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.1016\/j.bbmt.2009.12.057","article-title":"Prochymal Improves Response Rates In Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-GVHD) Involving The Liver And Gut: Results Of A Randomized, Placebo-Controlled, Multicenter Phase III Trial In GVHD","volume":"16","author":"Martin","year":"2010","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1016\/j.jcyt.2025.102012_bib0020","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bjh.12545","article-title":"Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III \u2013 IV acute graft-versus-host disease","volume":"163","author":"Ball","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2025.102012_bib0021","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.bbmt.2010.04.014","article-title":"Efficacy and Safety of Ex Vivo Cultured Adult Human Mesenchymal Stem Cells (ProchymalTM) in Pediatric Patients with Severe Refractory Acute Graft-Versus-Host Disease in a Compassionate Use Study","volume":"17","author":"Prasad","year":"2011","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1016\/j.jcyt.2025.102012_bib0022","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.bbmt.2020.01.018","article-title":"A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease","volume":"26","author":"Kurtzberg","year":"2020","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1016\/j.jcyt.2025.102012_bib0023","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.102012_bib0024","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events v5.0 (CTCAE).https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events#ctcae. Accessed February 15, 2025."},{"key":"10.1016\/j.jcyt.2025.102012_bib0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/scrt75","article-title":"Mesenchymal stem cell effects on T-cell effector pathways","volume":"2","author":"Duffy","year":"2011","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jcyt.2025.102012_bib0026","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/glia.20841","article-title":"Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis","volume":"57","author":"Bai","year":"2009","journal-title":"Glia"},{"key":"10.1016\/j.jcyt.2025.102012_bib0027","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1182\/blood-2004-02-0586","article-title":"Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells","volume":"105","author":"Jiang","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.102012_bib0028","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1089\/ten.tea.2010.0159","article-title":"Adipose-Tissue-Derived and Wharton\u2019s Jelly\u2013Derived Mesenchymal Stromal Cells Suppress Lymphocyte Responses by Secreting Leukemia Inhibitory Factor","volume":"16","author":"Najar","year":"2010","journal-title":"Tissue Engineering Part A"},{"key":"10.1016\/j.jcyt.2025.102012_bib0029","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1634\/stemcells.2006-0709","article-title":"Comparison of Proliferative and Multilineage Differentiation Potential of Human Mesenchymal Stem Cells Derived from Umbilical Cord and Bone Marrow","volume":"25","author":"Baksh","year":"2007","journal-title":"Stem Cells"},{"key":"10.1016\/j.jcyt.2025.102012_bib0030","doi-asserted-by":"crossref","first-page":"e9016","DOI":"10.1371\/journal.pone.0009016","article-title":"Pro-Inflammatory Cytokines, IFN\u03b3 and TNF\u03b1, Influence Immune Properties of Human Bone Marrow and Wharton Jelly Mesenchymal Stem Cells Differentially","volume":"5","author":"Prasanna","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2025.102012_bib0031","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cellimm.2010.06.006","article-title":"Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton\u2019s Jelly and bone marrow sources","volume":"264","author":"Najar","year":"2010","journal-title":"Cellular Immunology"},{"key":"10.1016\/j.jcyt.2025.102012_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.709225","article-title":"Persistency of Mesenchymal Stromal\/Stem Cells in Lungs","volume":"9","author":"Ferrini","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jcyt.2025.102012_bib0033","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12067","article-title":"WJMSC-derived small extracellular vesicle enhance T cell suppression through PD-L1","volume":"10","author":"Li","year":"2021","journal-title":"J of Extracellular Vesicle"},{"key":"10.1016\/j.jcyt.2025.102012_bib0034","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1002\/term.2453","article-title":"Ectopic bone formation by aggregated mesenchymal stem cells from bone marrow and adipose tissue: A comparative study","volume":"12","author":"Fennema","year":"2018","journal-title":"J Tissue Eng Regen Med"},{"key":"10.1016\/j.jcyt.2025.102012_bib0035","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/stem.1118","article-title":"Analysis of Tissues Following Mesenchymal Stromal Cell Therapy in Humans Indicates Limited Long-Term Engraftment and No Ectopic Tissue Formation","volume":"30","author":"Von Bahr","year":"2012","journal-title":"Stem Cells"},{"key":"10.1016\/j.jcyt.2025.102012_bib0036","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3389\/fimmu.2012.00345","article-title":"Application of MultiStem\u00ae Allogeneic Cells for Immunomodulatory Therapy: Clinical Progress and Pre-Clinical Challenges in Prophylaxis for Graft Versus Host Disease","volume":"3","author":"Vaes","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.102012_bib0037","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.3324\/haematol.2022.281269","article-title":"Minnesota acute graft-versus-host disease risk score predicts survival at onset of graft-versus-host disease after post-transplant cyclophosphamide prophylaxis","volume":"107","author":"Ardizzoia","year":"2022","journal-title":"Haematol"},{"key":"10.1016\/j.jcyt.2025.102012_bib0038","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/j.bbmt.2019.07.017","article-title":"Outcomes and Predictors of Response in Steroid-Refractory Acute Graft-versus-Host Disease","volume":"25","author":"Rashidi","year":"2019","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1016\/j.jcyt.2025.102012_bib0039","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bbmt.2011.06.012","article-title":"Steroid-Refractory Acute GVHD: Lack of Long-Term Improved Survival Using New Generation Anticytokine Treatment","volume":"18","author":"Xhaard","year":"2012","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1016\/j.jcyt.2025.102012_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/601953","article-title":"Steroid-Refractory Acute GVHD: Predictors and Outcomes","volume":"2011","author":"Westin","year":"2011","journal-title":"Advances in Hematology"},{"key":"10.1016\/j.jcyt.2025.102012_bib0041","unstructured":"Food and Drug Administration. FDA approves ruxolitinib for acute graft-versus-host disease.https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ruxolitinib-acute-graft-versus-host-disease; 2019. Accessed February 15, 2025."},{"key":"10.1016\/j.jcyt.2025.102012_bib0042","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1200\/jco.2011.29.15_suppl.6500","article-title":"Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1\/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF)","volume":"29","author":"Verstovsek","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2025.102012_bib0043","first-page":"LBA6501","article-title":"Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF)","volume":"29","author":"Harrison","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2025.102012_bib0044","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2025.102012_bib0045","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.bbmt.2019.12.124","article-title":"A Phase 2 Study of F-652, a Novel Tissue-Targeted Recombinant Human Interleukin-22 (IL-22) Dimer, for Treatment of Newly Diagnosed Acute Gvhd of the Lower GI Tract","volume":"26","author":"Ponce","year":"2020","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1016\/j.jcyt.2025.102012_bib0046","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S2666-6367(23)00105-7","article-title":"Final Safety and Efficacy Results from Equate, an Open-Label Study Evaluating Itolizumab, a Novel Targeted Anti-CD6 Therapy, in Newly Diagnosed Acute Graft-Versus-Host Disease","volume":"29","author":"Koreth","year":"2023","journal-title":"Transplantation and Cellular Therapy"},{"key":"10.1016\/j.jcyt.2025.102012_bib0047","doi-asserted-by":"crossref","first-page":"10495","DOI":"10.1182\/blood-2022-163027","article-title":"Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)","volume":"140","author":"Abedin","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.102012_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2023.101957","article-title":"Mesenchymal stem cell-derived exosomes for managing graft-versus-host disease: An updated view","volume":"81","author":"Shafeghat","year":"2023","journal-title":"Transplant Immunology"},{"key":"10.1016\/j.jcyt.2025.102012_bib0049","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/S0140-6736(04)16104-7","article-title":"Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells","volume":"363","author":"Le Blanc","year":"2004","journal-title":"The Lancet"},{"key":"10.1016\/j.jcyt.2025.102012_bib0050","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","article-title":"Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study","volume":"371","author":"Le Blanc","year":"2008","journal-title":"The Lancet"},{"key":"10.1016\/j.jcyt.2025.102012_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2019.100249","article-title":"Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: An updated systematic review and meta-analysis","volume":"19","author":"Thompson","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jcyt.2025.102012_bib0052","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13287-022-02751-0","article-title":"Current status of clinical trials assessing mesenchymal stem cell therapy for graft versus host disease: a systematic review","volume":"13","author":"Li","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jcyt.2025.102012_bib0053","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047559","article-title":"Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials","volume":"7","author":"Lalu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2025.102012_bib0054","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/asheducation-2017.1.693","article-title":"Graft versus tumor effects and why people relapse","volume":"2017","author":"Falkenburg","year":"2017","journal-title":"Hematology"},{"key":"10.1016\/j.jcyt.2025.102012_bib0055","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.3389\/fimmu.2018.03041","article-title":"Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease","volume":"9","author":"Chang","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.102012_bib0056","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.stem.2013.09.006","article-title":"Mesenchymal Stromal Cells: Sensors and Switchers of Inflammation","volume":"13","author":"Bernardo","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcyt.2025.102012_bib0057","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.891065","article-title":"Strategies for the induction of anti-inflammatory mesenchymal stem cells and their application in the treatment of immune-related nephropathy","volume":"9","author":"Zhou","year":"2022","journal-title":"Front Med"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925009077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925009077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T07:16:08Z","timestamp":1781334968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925009077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1465324925009077"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.102012","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 1b study on the safety of Wharton\u2019s jelly mesenchymal stromal cells in the treatment of acute graft-versus-host disease","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.102012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102012"}}